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Abstract: Clinical outcomes following stereotactic body radiation
therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) are
excellent, with local control rates ranging from 80% to 95% in
medically inoperable patients. Toxicity following SBRT has been
lower than expected, with exception for grade 3 to 5 events occur-
ring in patients treated with high doses to mediastinal structures. In
considering a randomized head-to-head comparison of SBRT versus
surgery for stage I lung cancer, the interpretation of clinical response
based on imaging is of great importance. This is because of the
opportunity to salvage SBRT local failure with surgery in operable
patients. The current literature is reviewed with respect to computed
tomography (CT) and positron emission tomography (PET) with
respect to response following SBRT. The reported toxicities follow-
ing SBRT for both peripheral and central lung cancers are also
reviewed.
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The reported local control rates using stereotactic bodyradiation therapy (SBRT) for stage I lung cancer are
excellent.1 As the duration of follow-up for SBRT increases,
patients and physicians remain encouraged by this technique.
However, these 80% to 95% local control rates are clinical,
largely based on a radiographic interpretation of response.
These rates have been obtained mostly in patients who are
medically inoperable due to underlying pulmonary or cardiac
disease. These patients have limited other options. Therefore,
treating physicians have been able to observe these radio-
graphic changes without considering surgical salvage for
local failure.
Surgery remains the standard therapy for patients with
operable stage I lung cancer. When considering a phase III
comparison of surgery and SBRT for operable patients with
stage I lung cancer, the evaluation of response takes on
greater importance. One would want to salvage local failures
on the experimental arm with lung resections. There are very
few data correlating clinical with pathological response fol-
lowing SBRT for lung cancer. In this article, the reported
literature about radiographic response including both com-
puted tomography (CT) and positron emission tomography
(PET) is reviewed as well as the literature with respect to
radiation pneumonitis and pulmonary function.
RADIOGRAPHIC RESPONSE TO SBRT
Computed Tomography
The rates of asymptomatic radiographic pneumonitis
are high, ranging from 60% to 100%, depending on the
series.2–8 Therefore, radiographic changes in the lung paren-
chyma are expected following SBRT. Investigators from
Hiroshima University Hospital in Japan9 have classified ra-
diographic radiation pneumonitis following SBRT (within 6
months) into five categories based on a previous classification
for three-dimensional conformal radiation therapy as follows10:
(1) diffuse consolidation, (2) patchy consolidation and ground-
glass opacity (GGO), (3) diffuse GGO, (4) patchy GGO, and
(5) no evidence of increasing density. Examples of each are
illustrated in Figures 1 to 3. Furthermore, radiation fibrosis
(occurring 6 months after SBRT) was characterized as
follows: (1) modified conventional pattern (consolidation,
volume loss, and bronchiectases similar to, but less extensive
than, conventional radiation fibrosis), (2) masslike pattern
(focal consolidation limited around the tumor), and (3) scar-
like pattern (linear opacity in the region of the tumor associated
with volume loss) (Figure 4).
In this report, 52 lesions were scored radiographically
for acute pneumonitis: 20 lesions (38.5%) demonstrated dense
consolidation, eight lesions (15.4%) demonstrated patchy con-
solidation and GGO, six demonstrated diffuse GGO, one (2%)
demonstrated patchy GGO, and 17 (32.6%) had no evidence of
increased density. Appearance of radiation fibrosis on CT was
scored as follows: 32 (61.5%) demonstrated a modified conven-
tional pattern, nine (17.3%) demonstrated a masslike pattern,
and 11 (21.2%) had a scarlike pattern. Correlation of radio-
graphic response with clinical symptoms for this group is shown
in Table 1 and discussed below.
PET
Two groups of investigators have reported early results
on PET following SBRT for lung cancer. Ishimori et al.11
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from Kyoto University in Japan performed a feasibility study
using both 18F-fluorodeoxyglucose (FDG) and 11C-methio-
nine imaging after treatment. Nine patients underwent imag-
ing. FDG and methionine studies were performed at 1 week
before and 1 to 8 weeks after SBRT. Of note, FDG and
methionine imaging interpretations were consistent for each
patient. Responses to SBRT were complete in two and partial
in seven patients. Tracer uptake was high initially in all nine
patients. Tracer uptake decreased gradually on follow-up
imaging in five patients. In contrast, tracer uptake did not
decrease steadily in four of the nine patients. Two patients
had a temporal elevation in tracer uptake 2 weeks after
treatment. The other two patients showed a delayed increase
in tracer uptake more than 3 months after treatment. In these
latter two patients, the CT scan demonstrated radiation pneu-
monitis within the treated volume.
FIGURE 1. Diffuse consolidation
after stereotactic body radiation
therapy. This patient received 54
Gy in three fractions to a left upper
lobe cancer prescribed to the 85%
isodose line. Her follow-up com-
puted tomography (CT) scan ob-
tained 6 weeks following SBRT
showed a radiographic response.
However, her chest CT at 6 months
was concerning for local recur-
rence. A flurodeoxyglucose positron
emission tomography (PET) was
obtained to help differentiate be-
tween recurrence and fibrosis. The
PET reading suggested an inflam-
matory response but could not rule
out recurrence. This patient has
been followed for 18 months and is
without recurrence.
FIGURE 2. Patchy consolidation
and ground-glass opacity (GGO)
after stereotactic body radiation
therapy. This patient received 60
Gy in three fractions to a right up-
per lobe cancer prescribed to the
80% isodose line. His follow-up
computed tomography (CT) scan
at 6 weeks showed stable disease.
CT at 6 months demonstrated an
improved response with residual
patchy consolidation and GGO.
Positron emission tomography
(PET) showed no evidence of resid-
ual cancer. This patient has been
followed for 20 months and is with-
out recurrence.
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Hoopes et al.12 from Indiana University also reported a
small series of 14 patients who underwent pre- and post-
SBRT FDG-PET imaging. Fourteen patients underwent serial
imaging pre-SBRT and at 2, 26, and 52 weeks post-SBRT.
The median maximal standard uptake value (SUVmax) pre-
SBRT was 8.7 (range, 1.37–15.22). Post-SBRT SUVmax
values at 2, 26, and 52 weeks were median 6.04 (range,
0.14–10.87), median 2.8 (range, 1.12–9.18), and median 3.58
(range, 0.06–14.61), respectively. The one patient with a
local failure showed an initial decrease in SUV followed by
a steady increase in SUV at the later time points. Four of the
14 patients had an initial increase in SUV at 2 weeks. Six of
13 patients with local control demonstrated an SUVmax3.5
at 12 months after treatment.
The above studies evaluating the role of PET after
SBRT are preliminary. The results suggest that the use of
FIGURE 3. No evidence of in-
creasing density. This patient re-
ceived 54 Gy in three fractions to
this right lower lobe cancer pre-
scribed to the 85% isodose line. His
follow-up computed tomography
scan demonstrated tumor regres-
sion followed by a complete radio-
graphic response. This patient re-
mains without evidence of
recurrence 36 months following
stereotactic body radiation therapy.
FIGURE 4. Scarlike pattern of radi-
ation fibrosis. This patient received
54 Gy in three fractions to his right
lung cancer. Computed tomogra-
phy (CT) obtained 6 weeks after
therapy demonstrated a radio-
graphic response. The CT and
positron emission tomography/CT
scans obtained 12 months after
therapy showed no evidence of re-
current cancer. A scarlike band is
seen posterior to the original tumor
location with associated volume
loss.
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11C-methionine offers no advantage to 18F-FDG. Posttreat-
ment SUVmax can remain elevated for an extended period
after SBRT, which is likely due to an inflammatory
response. PET trials using radiotracers that differentiate
between inflammation and tumor recurrence may be
helpful.
Clinical Symptoms of Toxicity
Lung toxicity scoring is reported using the Common
Toxicity Criteria (Version 3.0) adverse events (CTCAE)
(Table 2). Grade 1 and 2 toxicity can occur in as many as 8%
of patients.1 Grade 1 toxicity includes anorexia, fever, chills,
and general malaise that typically occurs within a few hours
of treatment. Other grade 1 toxicities can include cough, pain,
and skin erythema. The most common grade 2 symptoms
include a cough requiring narcotic cough suppressants, chest
or pleural pain, and dermatitis. The most common grade 3
events are radiation pneumonitis requiring oxygen or steroids
and radiation dermatitis.
Because radiographic changes are seen in the majority
but most do not develop clinical symptoms, Kimura et al.9
correlated radiographic changes with clinical symptoms. Ta-
TABLE 1. Appearance on Computed Tomography and Clinical Symptoms*
Grade 1 Grade 2 Grade 3 Total P†
Acute radiation pneumonitis
Diffuse consolidation 3 11 2 16 0.000675
Patchy consolidation and GGO 6 2 0 8 0.175
Diffuse GGO 4 2 0 6 0.479
Patchy GGO 0 1 0 1 0.286
No evidence of increased density 12 3 1 16 0.01314
Radiation fibrosis
Modified conventional pattern 12 14 1 27 0.0394
Masslike pattern 4 3 2 9 0.559
Scarlike pattern 9 2 0 11 0.0297
Total 25 19 3 47
GGO, ground-glass opacity.
*We regarded the five patients who were irradiated for two lesions at once as one patient, and the two patients who were
irradiated for two lesions at different times, with an interval of 6 months or more, as two patients each, i.e., four patients in total.
†p value was evaluated grade 1 versus grade 2 or 3.
From Kimura et al.9
TABLE 2. Common Toxicity Version 3.0 Criteria for Adverse Events in the Lung (CTCAE)
Adverse
Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Pneumonitis Asymptomatic, radiographic
findings only
Symptomatic, not interfering
with ADL
Symptomatic, interferes
w/ADL, O2 indicated
Life-threatening,
ventilator support
Death
Cough Symptomatic, nonnarcotic
medication
Symptomatic and narcotic
medication indicated
Symptomatic and
significantly
interfering w/sleep or
ADL
— —
Pain Mild, not interfering with
function
Moderate pain: pain or
analgesics interfering with
functioning but not with
ADL
Severe pain: pain or
analgesics severely
interfering with ADL
Disabling —
Esophagitis Asymptomatic pathologic,
radiographic, or endoscopic
findings only
Symptomatic: altered eating/
swallowing (i.e., oral
supplements); IVF 24 hr
Symptomatic and
severely altered
eating/swallowing:
IVF, tube feeding or
TPN 24 hr
Life-threatening
consequences
Death
Dermatitis Faint erythema or dry
desquamation
Moderate to brisk erythema:
patchy moist desquamation,
mostly confined to skinfolds;
moderate edema
Moist desquamation
other than skinfolds:
bleeding induced by
minor trauma or
abrasion
Skin necrosis or
ulceration or full-
thickness dermis:
spontaneous bleeding
Death
DLCO 90%–75% predicted 75% to 50% predicted 50% to 25% predicted 25% predicted Death
ADL, activities of daily living; IVF, intravenous fluids; TPN, total parenteral nutrition; DLCO, diffusion capacity of the lung for carbon monoxide.
Data from Cancer Therapy Evaluation Program, Common Toxicity Criteria (Version 3.0) adverse events, Division of Cancer Treatment of Diagnosis, National Cancer Institute,
National Institutes of Health, Department of Health and Human Services.
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ble 1 shows this correlation. Grade 2 or 3 symptoms occurred
in 22 of 47 patients (grade 3 events occurred in only three).
Clinical symptoms were statistically associated with acute
pneumonitis patterns of diffuse consolidation (p  0.0006)
and no evidence of increased density (p  0.03) as well as
radiation fibrosis patterns of modified conventional (p 
0.04) and scarlike (p  0.03).
Sampson et al.1 published a review of the SBRT liter-
ature that included 15 lung studies (683 patients). Toxicities
were reported using the CTCAE, v.3. The median fol-
low-up periods for these studies ranged from 7 to 60
months. The equipment varied by institution, including the
use of linear accelerators, a micotron, a megavoltage CT,
and a Cyberknife unit. Grade 5 toxicity was rare for lung
SBRT treatment (n  2, 0.3%). Overall grade 3 to 5 events
occurred in 15% of lung cancer patients. Table 3 shows the
clinical results for the 15 institutions delivering SBRT for
lung cancer.2– 6,13–22 Table 4 shows the dose fractionation
schemes employed by these institutions. Examples of
grade 3 to 5 adverse events from this review of the
literature are shown in Table 5.13,15,21 Based on these
experiences and others, using SBRT for central lesions
within 2 cm of the proximal bronchial tree may have a
much higher severe complication rate.
Timmerman et al.23 recently reported the results of an
institutional experience at Indiana University describing se-
vere toxicity for central tumors. The report includes 70
patients who were treated on a prospective protocol using
three fractions of 20 Gy for T1 tumors and three fractions of
22 Gy for T2 tumors. Of note, patients with centrally located
tumors were not excluded from this study. Fifty-eight of 70
patients were found to have grade 1 to 2 toxicity, consisting
mostly of fatigue, musculoskeletal discomfort, and radiation
pneumonitis. Most of these events occurred within 1 to 2
months of treatment and resolved within 3 to 4 months after
treatment. Eight of 70 patients experienced grade 3 to 4
toxicity, including a decline in pulmonary function tests
(PFTs), pneumonias, symptomatic pleural effusions, apnea,
and dermatitis. The time frame for these toxicities ranged
from 1.1 to 25.1 months (median, 7.6) from treatment com-
pletion. The data safety and monitoring committee deter-
mined that SBRT may have been related to the deaths of six
patients in this study, occurring at 0.6, 3.9, 12.1, 13.8, and
19.5 months after treatment. Four deaths were associated with
bacterial pneumonia. One patient died of complications of a
pericardial effusion after treatment of a tumor adjacent to the
mediastinum. Another death occurred in a patient treated for
a local recurrence at the carina, experiencing fatal hemopty-
sis. The authors determined that tumor location (hilar/peri-
central versus peripheral) was a strong predictor of toxicity
(p  0.004). Patients treated for peripheral tumors had a
2-year freedom from toxicity rate of 83% versus only 54% for
patients treated to hilar/pericentral tumors. Furthermore, four
of the six deaths occurred in patients receiving SBRT to
hilar/pericentral tumors. A second factor predictive for grade
3 to 5 toxicity was the gross tumor volume (GTV). Tumors
whose GTV exceeded 10 ml had an eightfold risk of grade 3
to 5 toxicity compared with smaller tumors (p  0.017).
Investigators from Aarhus University Hospital in Den-
mark carefully followed clinical symptoms in 28 patients
TABLE 3. Lung SBRT Literature Results
Author
No. of
Patients
NSCLC
(vs. mets)
(%)
Median
Lesion Size (ml)b
Total
Dose (Gy)
Crudelocal
Control (LC) (%)
Median
Follow-up Time,
mo (range)
Acute
Toxicity
(grade 1–2)
(%)
Acute
Toxicity
(grade 3–5)
(%)
Chronic
Toxicity
(grade 3–5)
(%)
Blomgren et al.13 13 18 48 15–45 94 8.2 NR NR 6
Uemetsu et al.19 45 35 7.2† (mean) 30–75 97 11 11 0 0
Wulf et al.21 26 44 57 30 85 8 22 0 7 (1 death)
Nakagawa et al.6 15 5 Lung, 4.5
(CW, 40)
15–25 95 10 0 0 0
Fukumoto et al.2 22 100 10† 48–60 94 24 (2–44) 27 0 0
Nagata et al.5 40 78 12.6 40–48 94 (lung ca)
67 (mets)
18–19 NR 0 0
Hof et al.3 10 100 12 19–26 80 14.9 0 0 0
Timmerman et al.17 37 100 22.5 24–60 84 (resp 87) 15.2 49 8 0
Hara et al.14 23 22 5.8 (mean) 20–30 83 13 13 4 0
Lee et al.4 28 32 41.4 (PTV) 30–40 89 18 0 0 0
Onimaru et al.15 45 57 9.2† 48–60 88 17 4 2, 1 death 0
Uematsu et al.18 50 100 17† 50–60 94 60 16 0 0
Whyte et al.20 23 65 NR
(range 0.5–65†)
15 91 (2/23) PD, NR) 7 0 0 0
11.5†
Onishi et al.16 245 100 11.5† 18–75 85.5 24 11 4 1.2
Wulf et al.22 61 33 22 10–26 95 (lung ca)
90 (mets)
9–11 16 0 0
Publications are listed in order of date of publication. NSCLC, non-small cell lung cancer; mets, metastatic lesions; CW, chest wall.
*Does not include grade 1 pneumonitis, see Results section.
b Data recalculated from original report to convert from centimeters to milliliters with the formula: volume of sphere  (  d3)/6.
From Sampson et al.1
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after SBRT for stage I lung cancer.24 Patients in this phase II
study were medically inoperable with a World Health Orga-
nization performance status of 2 or lower. All patients had
peripherally located cancers. Toxicity evaluation was per-
formed at baseline and repeated at 2 weeks and 2, 3, and 6
months after SBRT. The median follow-up was 6.7 months
(range, 2.1–7.5). Patients were given 45 Gy in three fractions to
the isocenter over 5 to 8 days. Baseline dyspnea was prevalent in
64% of patients before SBRT, consistent with documented
COPD as the sole reason for inoperability in 21 of 28 patients.
Aggravation of dyspnea occurred in 11 patients on follow-up;
four with a one-grade increase and seven with a two-grade
increase. The group studied various dose-volume parameters for
both ipsilateral and total lung volumes, including the volumes of
lung exceeding 5, 10, 13, 15, 17, 20, 25, 30, 35, and 40 Gy.
There was no statistical correlation of toxicity with any of these
dose-volume parameters. The group also tested the association
of pneumonitis toxicity with clinical factors such as age, gender,
performance status, cause of medical inoperability, tumor vol-
ume, and tumor location. The presence of chronic obstructive
pulmonary disease displayed the closest correlation (p  0.14)
with all seven patients experiencing a two-grade increase having
underlying COPD.
Ohashi et al.25 from Keio University in Japan prospec-
tively obtained formal pulmonary function studies in 15
patients after treated 17 lung lesions with SBRT. Patients
were given 40 to 60 Gy over five to eight fractions prescribed
to the 80% isodose line. PFTs were performed immediately
before SBRT and 1 year after treatment. Test parameters
included total lung capacity (TLC), vital capacity (VC),
forced expiratory volume in 1 second (FEV1), and diffusion
capacity of the lung for carbon monoxide (DLCO). There
were no significant changes in TLC, VC, or FEV1 after
SBRT. The mean percentage of change from baseline in
DLCO was significantly increased by 128%. This improve-
ment in DLCO was correlated to those who had been heavy
smokers before SBRT and stopped after therapy. With regard
to clinical symptoms, 13 of the 15 patients experienced grade
0 to 2 toxicity. One patient experienced dyspnea and cough
requiring narcotic antitussives and one had radiation pneu-
monitis requiring steroids. There was no correlation between
clinical symptoms of toxicity and PFTs.
TABLE 4. Lung Dosing SBRT
Author
Fraction Size (Gy)
(no. of fractions) Total Dose (Gy) BED (Gy) NTD (Gy) IDL
Blomgren et al.13 10–20 (1–3) 15–45 38–113 50 PTV
Uemetsu et al.19 6–15 (5–15) 30–75 144–188 120–156 80% IDL on CTV
Wulf et al.21 10 (3) 30 60 50 65%
Nakagawa et al.6 15–25 (1) 15–25 38–88 31–73 Peripheral dose
Fukumoto et al.2 6–7.5 (8) 48–60 77–105 64–88 80% to edge
Nagata et al.5 10–12 (4) 40–48 80–106 67–88
Hof et al.3 19–26 (1) 19–26 55–94 46–78 80% IDL on PTV, Rx to iso
Timmerman et al.17 8–20 (3) 24–60 43–180 36–150 80% IDL
Hara et al.14 20–30 (1) 20–30 60–120 50–100 Min dose to GTV
Leet et al.4 10 (3–4) 30–40 60–80 50–67 90% IDL to PTV
Onimaru et al.15 6–7.5 (8) 48–60 77–105 64–88 Iso
Uematsu et al.18 5–12 (5–10) 50–60 90–100 75–83 NR
Whyte et al.20 15 (1) 15 38 31 Periphery of GTV
Onishi et al.16 3–12 (1–22) 18–75 108 (median) 90 (median) @ iso
Wulf et al.22 10–26 (1) 10–26 20–94 17–78 100% to PTV/edge
SBRT, stereotactic body radiotherapy; BED, biological effective dose; NTD, normalized tissue dose; PTV, IDL, CTV, GTV, gross tumor volume; iso,
isodose line.
Data from Cancer Therapy Evaluation Program, Common Toxicity Criteria (Version 3.0) adverse events, Division of Cancer Treatment of Diagnosis,
National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
From Sampson et al.1
TABLE 5. Lung: Examples of Adverse Grade 3 to 5 Events in the SBRT Literature
Grade Site
Fraction
Size  no. of Fractions
NTD (compared
with 2-Gy fractions) Toxicity
3 Tracheal wall 10 Gy  2 33 Gy Chronic cough
3 Lesion near esophagus 7 Gy  4 40 Gy Ulcerative esophagitis
5 Tumor on pulmonary artery 10 Gy  3 50 Gy Pulmonary bleeding and death*
5 Lesion near esophagus 6 Gy  8 64 Gy Esophageal ulcer and death
SBRT, stereotactic body radiotherapy; NTD, normalized tissue dose compared with conventional 2-Gy fractions.
*This was a retreatment: 1 year before, this patient had 63 Gy conventional radiotherapy.
From Sampson et al.1
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CONCLUSIONS
The vast majority of patients treated thus far with
SBRT for stage I lung cancer have been inoperable due to
underlying medical conditions such as COPD or heart dis-
ease. The local rates are high, ranging from 80% to 95% in
various series. Local control has been scored clinically, often
by a radiographic response followed by a lack of progression.
Because this population has limited therapy options, close
follow-up is appropriate. However, when considering SBRT
for an operable population with stage I lung cancer, addi-
tional tools are needed to confirm local control. These pa-
tients would have an opportunity for salvage surgery for
persistent or recurrent local disease.
Approximately 60% to 100% of patients treated with
lung SBRT can be expected to have radiographic changes.
Acute radiographic changes can be scored into five catego-
ries: diffuse consolidation, patchy consolidation and (GGO),
diffuse GGO, patchy GGO, and no evidence of increasing
density. Tumor recurrence can be particularly difficult to
separate from diffuse or patchy consolidation. FDG-PET may
help if the treated volume is not FDG avid. However, PET
may show increased FDG uptake that could be either an
inflammatory response or tumor recurrence. Inflammatory
responses can persist on FDG-PET for greater than 12
months. Radiotracers that can distinguish between tumor
recurrence and inflammation may be beneficial. Studies
aimed to evaluate this are needed.
Only a few reports have carefully followed clinical
toxicity after SBRT. More data are needed to correlate tox-
icity with pulmonary function and dose-volume parameters.
Grade 1 to 2 events can be relatively common and are
self-limiting. Grade 3 and 4 toxicity is fairly uncommon,
occurring in 5% to 10 % of patients after SBRT. Most of the
accumulated grade 5 events have occurred when patients
received high-dose SBRT to centrally located tumors, such as
those near the trachea, primary bronchus, major blood vessel,
and pericardium. Investigations specifically aimed at this
patient population are ongoing.
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